Publication | Closed Access

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Flexible-dose Phase 3PsychiatryPsychotic DisorderMedicinePsychopharmacologySchizophreniaNeuropharmacologySocial SciencesPharmacotherapyDrug TherapyPharmacologyPsychopathology